The European Society for Medical Oncology Gastrointestinal Cancers Annual Congress 2024 (ESMO GI 2024)

A novel artificial intelligence (AI) classifier can detect hepatocellular carcinoma (HCC) signatures in routine blood tests up to 1 year before clinical diagnosis, as shown in a study from Hong Kong.

Treatment with the combination of regorafenib, nivolumab, and short-course radiotherapy (SCRT) in the neoadjuvant setting has induced response in stage II-III rectal adenocarcinoma in the phase II REGINA trial, meeting the predefined statistical criteria.

First-line treatment with nivolumab (NIVO) in combination with ipilimumab (IPI) results in better health-related quality of life (HRQOL) and fewer symptoms, when compared with chemotherapy, in patients with centrally confirmed microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (CRC), as shown in the CheckMate 8HW study presented at ESMO GI 2024.

Perioperative pembrolizumab plus chemotherapy confers survival benefit in individuals with locally advanced gastric and gastroesophageal junction (G/GEJ) cancer in the final analysis of the phase III KEYNOTE-585 trial.